Clinical Microbiology Market Growth Is Expected To Reach A Value Of USD 16.1 Billion By 2024

Key factors driving the market growth include constant introduction of advanced products coupled with increasing demand in pharmaceutical, and clinical applications for investigation and diagnosis of various infectious diseases.

The market is rapidly growing due to the increasing adoption of automated and advanced technologies for laboratory instruments and analyzers in developed countries. Growing geriatric population and thereby rising prevalence of infectious diseases is one of the major factors boosting the adoption of clinical microbiology in healthcare sector for disease diagnosis and monitoring. In addition, industry is gaining high momentum with launch of innovative products such as MALDI Biotyper, GeneXpert and Myla IT performance management solutions. Moreover, with the U.S. FDA approving the Xpert Carba-R, commercialization of clinical microbiology devices is expected to increase significantly over the next few years.

In North America, the government authorities and private companies have significantly contributed toward technology development, research funding, and commercialization of clinical microbiology associated devices.

View summary of this report, Click Here 

Further Key Findings from the Study Suggest:

• Rapid adoption of technology and automation of laboratory work flow, laboratory instrument segement is expected to be the fastest growing segment with CAGR of 8.6% over the forecast period.
• Reagents is the largest segment with market share of 34.7% in 2015. Repeat purchase of reagents contribute to its growth thus it is the largest growing segment in market.
• In 2015, North America dominated the global market with largest revenue share of 41.0%. The continuous research on infectious disease treatment, and subsequent grant from government healthcare agencies are contributing to the development of a strong ecosystem for the expansion of clinical microbiology in the region.
• Asia Pacific is expected to emerge as the fastest growing region during the forecast period. The growing geriatric population in India, China and Japan leading to increase in the prevalence of re-emerging infectious diseases such as tuberculosis, cholera and typhoid in this region are expected to promote the utilization of clinical application of microbiology in healthcare.
• The clinical microbiology Industry is presently dominated by a few key participants such as bioMerieux S.A., Cepheid Inc., Danaher Corporation and Bruker Corporation. Some of the prominent players operating in the market include but are not limited to Becton Dickinson & Company, Hologic Inc., Roche Diagnostics and Alere Inc. Introduction of automated systems and innovative designs, is expected to intensify the competition by changing the market dynamics over the forecast period.

Click Here For Access Full Report : https://goo.gl/k18t1S

Biological Safety Testing Market Growth Is Expected To Reach USD 5.54 Billion By 2024

The biological safety testing market is primarily driven by exponential growth in the production of biologics and medical devices that demand stringent safety requirements. The growing disease burden is anticipated to be the major cause for high production of biologics thus contributing toward market growth.

The overwhelming adoption rate of unhealthy lifestyles has resulted in the high prevalence of chronic diseases, such as cancer and diabetes, which is serving as a key contributing factor toward increasing drug development and their subsequent commercialization. This is presumed to raise the need to scrutinize and ensure the safety of targeted and specialized therapies, evaluate their outcomes, and circumvent probable shortcomings.

As a consequence of the high manufacturing intensity, pharmaceutical and biotechnology companies are increasingly incorporating biological safety testing tools to produce highly potent and contamination-free biologics to cater to the large population suffering from target diseases.

In addition, stringent regulations issued by healthcare organizations globally are presumed to be responsible for the high uptake of biological safety testing tools, thus resulting in a wider scope for the biological safety testing market

For instance, the European Medical Device Directives are believed to have a higher influence on the implementation of the defined imperative regulations to meet the growing safety requirements, thus translating into improved biological safety and contributing to overall growth of this vertical.

View summary of this report, Click Here

Further Key Findings From the Study Suggest:

• Reagents & kits held a substantial share of the product segment of over 42.0% in 2015 as it forms an indispensable part of the overall testing process and the high dependency of the testing results on the quality of reagents employed to perform the tests.

• In 2015, vaccine and therapeutics accounted for the largest market share in the application segment owing to the rising development of vaccines that are highly vulnerable to adventitious agents and necessitate stringent safety measures to prevent potential contamination due to unspecified agents

• The endotoxin tests held the largest share of 24.0% in the tests segment as of 2015. This large share is attributed to the high clinical urgency to reduce the threat of endotoxins during the development of bio-pharmaceuticals

• In 2015, North America dominated the regional biological safety testing vertical with a share of over 36.0%. The dominant share is a consequence of high investment in the biotechnology sector, its increasing adoption in cancer research, and for the development of new biologics, vaccines, and drugs.

• Asia Pacific is expected to witness growth at an exponential CAGR of over 13.0% during the forecast period. The exponential growth rate can be attributed to the increasing healthcare spending, the demand for better infrastructure quality in laboratory & clinical research, and the adoption of compact and low cost techniques in clinical research.

• The prominent players are involved in undertaking new product development and collaborative strategies to gain a higher share of the vertical. For instance, in June 2016, Charles River acquired Blue Stream Laboratories, Inc., an analytical contract research organization. This acquisition was carried out to enhance its existing capabilities in safety assessment and manufacturing of biologics.

Click Here For Access Full Report : https://goo.gl/BFDYWU

Electrodes For Medical Devices Market Growth Is Expected To Reach USD 2.0 Billion By 2025

The market is anticipated to witness lucrative growth during the forecast period, owing to increasing prevalence of chronic and other diseases such as heart diseases, Parkinson’s Disease (PD), Alzheimer’s disease, brain disorders, Trigeminal Neuralgia (TN or TGN), sinusitis, tinnitus, Raynaud's disease, fibromyalgia, circulatory disturbances, gout, and body ache, across the globe. 

Minimally Invasive Surgery (MIS) is one of the advancements in medical technology in which small incisions are made in the body for laparoscopy, endoscopy, arthroscopy, and other surgical procedures. This procedure is gaining popularity owing to faster recovery, lesser postsurgical infections, pain, & major bleeding, reduced scarring, and high accuracy benefits. In 2015, over 20.0 million Americans underwent MIS, which is expected to assist in the growth of this vertical during the forecast period.

View summary of this report, Click Here 

Further Key Findings From the Study Suggest:

• The diagnostic segment held a profitable revenue share in 2016 and is expected to grow at a significant rate over the forecast period.
• Rising prevalence of heart diseases, fetal distress syndrome, ocular diseases, and neurological disorders make extensive use of Electrocardiogram (ECG), Electroencephalogram (EEG), electrosurgical, and fetal scalp electrodes
• The therapeutic segment is anticipated to witness the fastest growth over the forecast period due to widened use of medical electrodes in aesthetic surgeries, RF ablation procedures, neurosurgical procedures, and acute & chronic pain treatments
• Defibrillator and electrosurgical electrodes are projected to hold substantial market share over the forecast period. This can be attributed to the advanced development of wearable defibrillator that constantly monitors the cardiac rhythms of the wearer and identifies & notifies the user about the occurrence of any abnormality and helps regain the normal heart functionality
• North America is expected to dominate the medical electrodes market during the forecast period, owing to the rising prevalence of CVDs, changing lifestyle of individuals, and presence of target population in the U.S. and Canada. In addition, the presence of advanced technologies with electrodes such as hydrogel and dry electrodes in the region are expected to spur the medical electrodes market growth.
• Some of the key players in medical electrodes market are 3M Healthcare; Boston Scientific Corporation; GE Healthcare; C.R Bard Inc.; CONMED Corporation; Medtronic; Natus Medical Incorporated; Thermo Fisher Scientific Inc.; Asahi Kasei Corporation; and Philips Healthcare

Click Here For Access Full Report : https://goo.gl/nVmyOV

Tourniquet systems market growth is expected to reach USD 594.8 million by 2025

Growing incidence of industrial & road accidents and major falls has been a major factor driving market growth. In addition, rapid increase in the number of hospitals and surgical care centers has led to increased application of tourniquets.

Tourniquets are majorly used when hemorrhages cannot be controlled with direct pressure or selective clamping of bleeding vessels. Certain advantages in modern surgical tourniquet systems such as safety, accuracy, and reliability have resulted in widespread adoption of these devices in orthopedic surgeries. Furthermore, technologically advanced tourniquet systems are now integrated with a wide range of pneumatic cuffs that help optimize the performance of the overall system. However, reusable cuffs might result in transmission of infection, which would consequently raise hospital costs and may hinder the growth of market during the forecast period.

View summary of this report, Click Here 

Further key findings from the report suggest:

• The market study suggests that tourniquet cuffs dominated the overall market in 2016 owing to their increasing applications in orthopedics, trauma, and emergency settings.
• Amongst the application segments, hospitals occupied the largest share as they are effective in arresting life‐threatening external hemorrhage caused due to limb injury
• In addition, the non-institutional application segment is expected to grow rapidly due to the potential application of tourniquets in military war settings.
• The Advanced Trauma Life Support (ATLS) recommends that “the judicious use of a pneumatic tourniquet may be helpful and lifesaving” in cases of major arterial hemorrhage caused by military wars
• North America dominated in 2016 owing to presence of an excellent healthcare infrastructure, rise in the number of road accidents, and increasing adoption of advanced tourniquet devices
• The Asia Pacific region is anticipated to witness significant growth during the forecast period. It will have one of the widest consumer base of tourniquets owing to huge population, increasing industrial & road accidents, and commendable financial support from various governments.
• Some of the major companies operating in this market are Delfi Medical, Zimmer Biomet, Hammarplast Medical AB, VBM Medizintechnik GmbH, Stryker, ulrich medical, and Rudolf Riester GmbH

Click Here For Access Full Report : https://goo.gl/JhKDGV

Perfusion Systems Market Growth Is Expected To Reach USD 183.8 Million By 2025

Rising demand for transplantation owing to increased incidence of vital organ failures is a major growth driver of the market. To curb this problem, Machine Perfusion (MP) is adopted by clinics. Hence, demand for the same is expected to grow over the coming years.

Statistics published by the National Kidney Foundation in 2014 states that 4,761 patients died due to unavailability of a kidney. This showcases the need for viable donated organs for transplantation, thereby boosting market growth.

The introduction of technologically advanced products for the purpose of enhanced efficiency and cost-effectiveness is expected to serve this market with lucrative opportunities. For instance, introduction of portable organ perfusion systems is presumed to gain popularity over the coming years owing to associated benefits with its usage such as ease of access, cost-efficiency, and portability.

Market participants are involved in extensive R&D for development of innovative perfusion techniques. For instance, TransMedics, Inc. carried out the world’s first warm blood perfusion liver transplantation with its innovative TransMedics Organ Care System Liver technology.

Moreover, many of market players in the U.S. and Europe are involved in the development of new products that are in clinical trials. For example, METRA developed by OrganOx Ltd. for automatic liver transportation and normothermic liver perfusion is under clinical study in the U.S. The expected product approvals in the coming years are anticipated to serve this industry with lucrative growth opportunities.

View summary of this report, Click Here 

Further Key Findings From the Study Suggest: 

• Presence of government initiatives such as National Organ Transplant Programme in India and initiatives from nonprofit organizations such as Donate Life America in the U.S. are contributing toward increasing awareness level
• Introduction of warm blood perfusion technology is expected to offer this industry with future growth opportunities
• Hypothermic MP held the dominant share as of 2016 owing to increasing adoption for kidney preservation. These systems are capable of preserving an organ for a longer duration as compared to static cold storage. The associated benefits with the use of this technology is expected to fuel the demand
• The MP technology for kidney transplantation segment held a dominant share as of 2016 owing to benefits attached to its usage
• As of now, there are two MP systems that are approved by the U.S. FDA including LifePort Kidney Transporter by Organ Recovery Systems Inc. and WAVES RM3 by Waters Medical Systems
• The Asia Pacific regional industry for MP is expected to witness lucrative CAGR during the forecast period
• The industry participants are focusing toward the development of cost-effective solutions, thereby increasing R&D activities for the development of novel technologies.

Click Here For Access Full Report : https://goo.gl/mQ3R7f

Protein Expression Market Growth Is Expected To Reach USD 3.0 Billion By The Year 2025

The global protein expression market is expected to reach USD 3.0 billion by the year 2025 growing at a CAGR of 10.4%, according to a new report by Grand View Research, Inc. The growing demand for biologics and expansion of the biopharmaceutical industry have resulted in massive growth of the protein expression market. Rising demand for therapeutic proteins such as insulin, hormones, monoclonal antibodies,and vaccines is a major factor that propels growth of the market during forecast period. Thus, many biotechnology and pharmaceuticals companies have begun to concentrate on the development and manufacturing of advanced therapeutic proteins for the treatment of severe chronic diseases such as cancer, hemophilia, infectious diseases, anemia, and multiple sclerosis.

Increasing investment in the R&D, by biotechnology and pharmaceutical companies, is another major factor supporting the sector growth. The availability of new and advanced technologies to cater the needs of drugs & biologics product manufacturers boosts the adoption of protein expression products for research and manufacturing applications. In addition, several pharmaceutical and biotechnology manufacturers are undergoing collaborations and partnerships to achieve leadership in the sector. For instance, in December 2016, Takara Bio, Inc. signed a merger agreement with Rubicon Genomics, Inc. to strengthen its genomics business.

View summary of this report, Click Here 

Further Key Findings From The Report Suggest:

• Prokaryotic expression systems segment was the largest revenue-generating amongst others owing to its large application in biologics and drug productions
• Mammalian cell expression systems is the fastest growing segment of the protein expression market owing to its growing demand for proteomics research and biologics manufacturing
• Reagents segment held the largest revenue share in the market, which is attributed to its repetitive purchase fortherapeutic, industrial, and research applications
• The services segment is projected to grow at highest rate due to increasing trend of outsourcing of protein expression services by research labs and drug manufacturers
• Therapeutic application segment was leading in 2016, due to high demand of therapeutic proteins for the treatment of cancer, infectious diseases, anemia, hemophilia, and multiple sclerosis
• The pharmaceutical and biotechnological companies segment dominated the sector in terms of revenue in 2016 due to rising focus on proteomics research and increasing production of biologics products
• North America was the leading regional market in 2016 and is expected to maintain its dominance during the forecast period, because of the presence of large number of biopharmaceutical and biotechnology companies in this region
• The Asia Pacific region is projected to grow at a highest CAGR during the forecast period owing to untapped opportunities in the developing countries including China and India

• Some of the major players include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Merck KGaA, New England Biolabs, Promega Corporation, Qiagen, and Takara Bio, Inc.  

Click Here For Access Full Report : https://goo.gl/wju9Jf

Blood Culture Tests Market Growth Is Expected To Reach USD 6.6 Billion By The Year 2025

The increasing prevalence of bloodstream infections and infectious diseases is the most significant factor anticipated to propel the market growth during the forecast period. Increasing demand for advanced diagnostic techniques for the diagnosis of infectious diseases, such as sepsis, is the main factor that drives growth of the market. Thus, many manufacturing companies have begun focusing on development of advanced diagnostic instruments and consumables.

The introduction of various government initiatives pertaining to the prevention and control of infections is likely to propel the demand for blood culture tests. According to CDC, there was 46% decrease in central line-associated bloodstream infections between 2008 and 2013 in the U.S., owing to efforts taken by the U.S. government for the prevention of hospital-acquired infections.

View summary of this report, Click Here 

Further key findings from the report suggest:

• Conventional blood culture technique is the largest revenue-grossing segment owing to huge applications of this method in hospitals, independent clinical laboratories, and pathology laboratories
• In the product segment, consumables accounted for the largest revenue share in 2016, due their huge applications in diagnostics & research, with repetitive purchase of these consumables, such as blood culture media, assay, kits, and reagents, adding to the revenue
• Automated blood culture systems segment is the fastest growing segment of the blood culture tests market owing to the advantages of automation, such as low chances of error, faster result generation, etc.
• Molecular technology segment is projected to grow at the highest CAGR, because of increasing demand for advanced products by hospitals and laboratories for diagnosis of infectious diseases
• Bacterial infections accounted for the largest revenue share in 2016, due to the fact that they are the most common cause for infection in the blood
• Reference laboratories is projected to grow at the highest rate during the study period, because there is an increase in outsourcing of blood tests by hospitals to reference laboratories
• North America is the leading regional sector that accounted for the largest revenue share of the blood culture tests market in 2016, because of the presence of well-developed healthcare infrastructure in this region
• The Asia Pacific region is anticipated to grow at the highest CAGR during the forecast period owing to increased focus of government on the prevention of infectious diseases
• Some of the major players are Becton, Dickinson and Company; bioMérieux SA; Thermo Fisher Scientific, Inc.; Danaher Corporation; Luminex Corporation; Roche Diagnostics; Bruker Corporation; Abbott Laboratories; and Alere

Click Here For Access Full Report : https://goo.gl/Cpz4aZ